Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

Long-term Biological Treatment in Juvenile Idiopathic Arthritis: Benefits and Risks

Duca Emanuela, Harabagiu Marin, Maguran Ioana, Samasca Gabriel, Sur Genel*

Iuliu Hatieganu University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania

Abstract: The advent of biologic medication has substantially improved the evolution of juvenile idiopathic arthritis (JIA), producing better social insertion and a clearly superior quality of life. However, there is a possibility of immunological disorders following treatment with biological substances, which may have long-term consequences in treated patients. The extension of clinical trials to pediatric patients has allowed a closer follow-up of both the evolution of the disease under treatment and the consequences of biological treatments. This article aims to analyze this aspect according to studies conducted in many countries by several authors. For each biological agent, the immunological events consisted primarily of the appearance of serious infections, such as tuberculosis, malignancies, response to vaccines, the appearance of autoimmune manifestations, and, last but not least, the appearance of anti-drug antibodies. These studies have shown that there are large differences in side effects between different biological agents, and, therefore, it has been proposed that a dossier be conducted to monitor these side effects. An international pharmacovigilance database called PharmaChild has already been created.

Keywords: juvenile idiopathic arthritis, biologic medication, benefits, risks

Received July 22, 2022; Revised August 24, 2022; Accepted September 05, 2022

Citation: Duca Emanuela, Harabagiu Marin, Maguran Ioana, Samasca Gabriel, Sur Genel, Long-term Biological Treatment in Juvenile Idiopathic Arthritis: Benefits and Risks. International Journal of Celiac Disease, 10 (1). 17-19. January 2022. doi:10.12691/ijcd-10-1-5

1. Introduction

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children. The incidence at a European level is 16 to 150 per 100 inhabitants per year [1]. JIA can cause short and long-term disabilities. JIA is a disease with no apparent cause that lasts more than 6 weeks, with onset at the age of 16 years. The 7 subtypes of JIA differ in genetic susceptibility, distribution in the infant population, and severity of arthritis [2]. Systemic JIA accounts for up to 17% of all JIA cases. It turned out that this is a totally different disease from the other subtypes, both in its manifestations and in its evolution and response to therapy. In the last decade, legislation has been implemented to encourage controlled clinical trials in children, as well as the introduction of new powerful biologic drugs, which have greatly improved the course of the disease. These biological drugs are produced by biological processes [1,3].

The American College of Rheumatology mentioned, in 2011, six biological substances in the treatment of JIA. These drugs are TNF-α inhibitors - 3 types: Etanercept, Adalimumab, Infliximab; Immunoglobulins CTLA4, such as Abatacept; Anti-CD20 monoclonal antibodies (mAb), such as Rituximab and an IL-1 antagonist - Anakinra. An IL-6 anti-receptor agent, Tocilizumab, has also been introduced. Difficulties in tracking the biological effects and specific indications of these treatments are related to safety issues, common side effects, small patient populations and too short follow-up time [4,5,6,7].

2. Clinical and Immunological Aspects of Long-term Use of Immunological Therapy in Children with JIA

There are many immunological differences in the actions of these biological substances. Those drugs, which target TNF-α, have a high potency for binding TNF-α and forming complexes. It is interesting to note that among the 3 drugs which bind to TNF-α, Etanercept has a particular action, in the sense that it lacks the first part of the CH1 constant antibody region [8,9]. Due to this particular structure, cytotoxicity does not occur, because the complement does not participate in this type of reaction. Usually, complement 3 (C3) binds to the CH1 portion of the antibody and forms the membrane attack complex. Therefore, the fact that Etanercept does not induce this type of reaction means it has low toxicity. The other 2 drugs, Infliximab and Adalimumab, induce complement-dependent cytotoxicity. Very important for biologics is the half-life, which differs as follows: Adalimumab has a half-life (T1/2) of 2 weeks and Anakinra T1/2 of 4-6 hours, thus it should be injected daily [10,11,12,13].

Very common side effects differ for each agent and mainly refer to lower respiratory tract infections, headaches, etc. The time to assess the effectiveness of the drug is 3-4 months.

If the answer is not appropriate, we should consider changing the medicine. It is important to note that these biological drugs antagonize the cytokines or receptors involved in the immune system. This leads us to think about the possibility of affecting the quality of the immune system and, through this, the emergence of a defective defense mechanism against infections and tumors, ineffective responses to vaccinations, and poor immunoregulation can occur, which can promote autoimmunity or autoinflammation [1,14,15]. It should be noted that antibodies (Ab) may be produced against the biological drug because it can be recognized as an antigen by the immune system. Some similarities may occur in patients with JIA treated with biological substances and patients with primary immunodeficiency. For this reason, tests for primary immunodeficiency may be performed to estimate possible side effects. Most of the studies analyzed show that bacterial infections are those that require antibiotic therapy and hospitalization. It is also known that Anakinra and Tocilizumab, as well as corticosteroids, can affect body temperature without a patent fever and can also affect the production of acute phase reactants. It has also been found that the two substances can also induce neutropenia. For these reasons, great care must be taken to diagnose an infection during this treatment [16,17,18].

3. Opportunistic Infections

Opportunistic infections were found in 0.3 per 100 patients with JIA in a cohort of 8,503 children. The responsible pathogens included Coccidioides, Salmonella, and Shigella. In the case of biological treatments, it was found that Etanercept did not cause any serious infections that required hospitalization. Other biologic drugs have caused infections in different percentages, some of them insignificant [1,19].

4. Tuberculosis

Tuberculosis, which is a serious infection, has occurred in cases treated with Infliximab, even in countries where there is no increased incidence of tuberculosis. For this reason, TNF-α inhibitors should not be used in patients with latent tuberculosis. TB testing is mandatory prior to treatment with TNF-α inhibitors. It is preferable to use more sensitive tests for patients before therapy. One such test would be an immunosorbent assay (IGRA QuantiFERON GOLD).

In 2012, the American College of Rheumatology recommended testing all patients who are treated with biological agents. Studies have shown that for most biological agents, no cases of TB have occurred with treatment [1].

5. Malignant Diseases

Cases of malignancy have been reported in children and adolescents treated with TNF-α antagonists. In patients treated with TNF-α antagonists, an increased rate of malignancy and, in particular, lymphoproliferative diseases was detected.

Regarding the administration of vaccines to patients with JIA being treated with biologic drugs, it shows that live attenuated vaccines are safe in patients receiving biologic drugs. Methotrexate alone, used in the treatment of JIA, reduces the response to the pneumococcal vaccine, independent of T cells [1,20].

6. Autoimmune Diseases

The emergence of new autoimmune diseases may be possible during treatment, given the potential of these drugs to create immune system dysfunction. It is known that uveitis can occur in JIA but also in 1.3% of patients with Crohn's disease. Here, it is difficult to interpret whether it is caused by the disease or could be sustained by biological treatment. Several studies have reported the development of demyelinating diseases, especially those with TNF-α inhibitors, which is why warnings and precautions have been sent to TNF-α blockers [1,11].

7. Conclusions

It is very difficult to assess the incidence of side effects, which are attributed only to biological drugs. However, what we can remember is that these biological drugs, which have brought great changes for the better in the evolution of JIA, should be used with caution in certain categories of patients. We must also be careful about the way these medicines work and to not administer them to those with a potential risk for severe respiratory infections, those with a potential risk for malignancy or latent tuberculosis. We must consider other possible complications and associations, as has been recently described in some patients with JIA, treated with biological agents, the appearance of essential pulmonary hypertension, interstitial lung disease, and alveolar proteinosis.

It seems that these complications are the result of severe uncontrolled systemic activity. We must also take into account the fact that in the treatment of JIA, drug combinations are also used, and in order to appreciate the side effects, we must take into account these combinations. For better management of these adverse side effects, national registries should be created for patients treated with JIA, and side effects should be monitored consistently. In fact, the European Union (EU) funded Pharma Child platform has also been launched, which is, in fact, a web registry that will provide better insights into the real immunological consequences of biologics. The immunological consequences of long-term use of biologic medications differ between the types of medication and their combination. It is known that infections can occur in JIA more frequently even without biological treatment. Malignant tumors may occur more frequently in patients using TNF-α inhibitors. The response to vaccination is good in patients with JIA. Demyelinating diseases have also been described in the peripheral system, so they will have to be recorded in the future as a possibility of autoimmunity, especially in patients treated with TNF-α inhibitors.

References

[1]   | Swart JF, de Roock S, Wulffraat NM. What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? Arthritis Research & Therapy 2013; 15: 213.
[2]   | Sur L, Sur G, Samasca G, Lupan I. Investigations of cellular immunity in juvenile idiopathic arthritis. Cent Eur J Immunol 2019; 44: 92-96.
[3]   | Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis 2018; 77: 1710-1719.
[4]   | Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J 2017; 15: 86.
[5]   | Sur LM, Floca E, Sur DG, Colceriu MC, Samasca G, Sur G. Antinuclear Antibodies: Marker of Diagnosis and Evolution in Autoimmune Diseases. Lab Med 2018; 49: e62–e73.
[6]   | Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2012; 22: 109-115.
[7]   | Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015; 74: 1110-1117.
[8]   | Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol, 2021; 17: 257-269.
[9]   | Gerss J, Tedy M, Klein A, Horneff G, Miranda-Garcia M, Kessel C, et al. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Ann Rheum Dis 2022 Mar 8; annrheumdis-2021-222029.
[10]   | Nagy A, Mosdosi B, Simon D, Dergez T, Berki T. Peripheral Blood Lymphocyte Analysis in Oligo- and Polyarticular Juvenile Idiopathic Arthritis Patients Receiving Methotrexate or Adalimumab Therapy: A Cross-Sectional Study. Front. Pediatr 2020; 8: 614354.

[11]  
Brunner HI, Quartier P, Alexeeva E, Constantin T, Koné-Paut I, Marzan K, et al. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. Arthritis Rheumatol 2020; 72: 2147-2158.

[12]   | Sur LM, Gaga R, Duca E, Sur G, Lupan I, Sur D, et al. Different Chronic Disorders That Fall within the Term Juvenile Idiopathic Arthritis. Life 2021; 11: 398.
[13]   | Wu J, Sun L, Tang X, Zheng Q, Guo L, Xu L, et al. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis–associated refractory macrophage activation syndrome. Mod Rheumatol 2021.
[14]   | Sur LM, Silaghi C, Colceriu MC, Sur DG, Aldea C, Sur G, et al. Immunology markers that can be predictive for the diagnosis of juvenile idiopathic arthritis. Journal of Laboratory Medicine 2020; 44: 23-26.
[15]   | Sur LM, Armat I, Duca E, Sur G, Lupan I, Sur D, et al. Food Allergy a Constant Concern to the Medical World and Healthcare Providers: Practical Aspects. Life 2021; 11: 1204.
[16]   | Katsicas, M.M., Russo, R.A.G. (2020). Systemic-Onset Juvenile Idiopathic Arthritis. In: Cimaz, R. (eds) Periodic and Non-Periodic Fevers. Rare Diseases of the Immune System. Springer, Cham.
[17]   | Florian A, Lupan I, Sur L, Samasca G, Florian T. To be, or not to be… Guillain-Barré Syndrome. Autoimmun Rev 2021; 20: 102983.
[18]   | Vastert SJ, Jamilloux Y, Quartier P, Ohlman S, Koskinen LO, Kullenberg T, et al. Anakinra in children and adults with Still’s disease. Rheumatology 2019; 58: vi9-vi22.
[19]   | Sur L, Gaga R, Lazar C, Lazea C, Aldea C, Sur D. Papillary thyroid carcinoma in children with Hashimoto's thyroiditis-A review of the literature between 2000 and 2020. J Pediatr Endocrinol Metabol 2020; 33: 1511-1517.
[20]   | Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008; 359: 810-820.